osimertinib

Drugmakers Push to Improve Treatment in Key NSCLC Subgroups, Find Options Where There Are Few

AstraZeneca Q1 Oncology Product Sales Increase 14 Percent Led by Tagrisso

Hutchmed Receives $15M Milestone Payment From AstraZeneca in Orpathys Codevelopment Deal

RedCloud Bio to Begin Trial of Fourth-Generation EGFR Inhibitor in NSCLC Subgroup

AstraZeneca Q4 Oncology Revenues Grow 20 percent

In Brief This Week: AstraZeneca, Daiichi Sankyo, Orgenesis, Amgen

NICE Backs AstraZeneca's Tagrisso for Adjuvant EGFR-Mutated NSCLC Through Cancer Drugs Fund

Hutchmed, AstraZeneca Begin Phase III Trial in NSCLC With EGFR, MET Mutations

AstraZeneca's Q3 Oncology Revenues Grow 18 Percent

In Brief This Week: AstraZeneca, CytoDyn, BerGenBio, Bayer, Dana-Farber Cancer Institute, Kronos Bio

ESMO Data Shed Light on Activity of Janssen's Rybrevant-Leclaza Combo in EGFR-Mutated NSCLC

Erasca Begins HERKULES-2 Trial of ERAS-007, Tagrisso in EGFR-mutated NSCLC

AstraZeneca, Hutchmed Launch Phase III Randomized Trial of Orpathys, Tagrisso in China

AstraZeneca Q2 Revenues Increase 31 Percent

Genecast to Evaluate Liquid Biopsy EGFR Mutation Test in Early-Stage Non-Small Cell Lung Cancer

UK's MHRA Grants Early Access to AstraZeneca's Tagrisso as Adjuvant NSCLC Treatment

AstraZeneca's Tagrisso Recommended by EMA Committee in Adjuvant NSCLC